Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Transgenic Group's Revenue for the
three
months ended in Mar. 2026 was 円3,479 Mil. Transgenic Group's average Accounts Receivable for the
three
months ended in Mar. 2026 was 円1,160 Mil.
Hence, Transgenic Group's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.00.
Transgenic Group (TSE:2342) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Transgenic Group Receivables Turnover Related Terms
Transgenic Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Transgenic Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2342 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Transgenic Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Transgenic Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a Receivables Turnover of 3.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Transgenic Group and its competitors. According to the industry distribution chart, Transgenic Group ranks #145 out of 842 companies in the Biotechnology industry, placing it in the top 17.2%.
Is Transgenic Group's Receivables Turnover too high?
Transgenic Group's current Receivables Turnover is 3.00. The Biotechnology industry median Receivables Turnover is 5.27. Transgenic Group's value of 3.00 is 43% below this industry median. Based on the distribution chart, Transgenic Group ranks #145 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Transgenic Group has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #145 out of 842 companies for Receivables Turnover. This places Transgenic Group in the top 17% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Transgenic Group's value of 3.00 is 43% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgenic Group's current Receivables Turnover of 3.00 is 43% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current Receivables Turnover is 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円255.65, compared to a current price of 円231.00 — trading 9.6% below its estimated fair value. The current Receivables Turnover is 3.00 and 43% below the Biotechnology industry median of 5.27. Transgenic Group's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Receivables Turnover is 3.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円231.00 is trading 9.6% below its estimated GF Value™ of 円255.65.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
Receivables Turnover: 3.00
GF Value™: 円255.65 vs. price of 円231.00 (9.6% below fair value)
Industry Position: 43% below the Biotechnology median (#145 of 842)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
61GF Score
Get the complete analysis for TSE:2342
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
